Introduction
VHT vs IBB is a common comparison for investors seeking exposure to the healthcare industry. Vanguard’s Broad Health Care ETF (VHT) tracks a wide slice of the sector, while iShares Biotechnology ETF (IBB) focuses on the biotech niche. Both funds have distinct cost structures, performance histories, and risk characteristics that shape their suitability for different investment goals.
As of September 28, 2026, VHT trades at $320.74 and IBB at $210.71. Their expense ratios differ markedly: VHT charges 0.09% and IBB 0.44% (Source: The Motley Fool coverage article, 2026-10-05). These figures set the stage for a deeper look at how each ETF performs and what investors can expect.
What Changed? Recent Performance Snapshot
The most recent data shows a stark contrast in short‑term performance. Over the past year, IBB delivered a 49.8% return, while VHT posted 22.5% (Source: The Motley Fool coverage article, 2026-10-05). However, the longer‑term picture tells a different story. Over five years, IBB’s maximum drawdown reached 39.8%, nearly double VHT’s 17.7% (Source: The Motley Fool coverage article, 2026-10-05). This divergence illustrates how biotech’s high volatility can amplify both gains and losses.
Key Benefits of VHT
Broad Diversification
VHT holds 411 individual stocks, covering pharmaceuticals, medical devices, and health services. Its largest positions—Eli Lilly & Co (12.82%), Johnson & Johnson (8.74%), and AbbVie Inc (6.27%)—represent a mix of established players across sub‑segments (Source: The Motley Fool coverage article, 2026-10-05). This breadth reduces concentration risk compared to a more focused biotech fund.
Lower Cost and Higher Yield
With an expense ratio of 0.09%, VHT is the more affordable option. It also offers a dividend yield of 1.4%, versus IBB’s 0.2% (Source: The Motley Fool coverage article, 2026-10-05). Over the trailing 12 months, VHT paid $4.61 per share in dividends, while IBB paid $0.34 (Source: The Motley Fool coverage article, 2026-10-05). For income‑oriented investors, VHT’s yield can be a decisive factor.
Stability
VHT’s beta of 0.58 indicates lower sensitivity to market swings, and its 5‑year maximum drawdown of 17.7% reflects a more stable performance profile (Source: The Motley Fool coverage article, 2026-10-05). This makes VHT suitable for investors with a moderate risk tolerance.
Key Benefits of IBB
Concentrated Biotech Exposure
IBB focuses on 243 biotech names, with Gilead Sciences (8.16%), Vertex Pharmaceuticals (7.65%), and Amgen Inc (7.53%) as its top holdings (Source: The Motley Fool coverage article, 2026-10-05). This concentration can capture the high growth potential of breakthrough therapies.
Higher Short‑Term Returns
IBB’s 1‑year return of 49.8% outpaces VHT’s 22.5% (Source: The Motley Fool coverage article, 2026-10-05). For investors willing to accept higher volatility, IBB can deliver superior upside.
Growth Potential
If a $1,000 investment in IBB grew to $2,224 over five years, compared with $828 for VHT, the compound annual growth rate for IBB is markedly higher (Source: The Motley Fool coverage article, 2026-10-05). This illustrates the potential for outsized returns in the biotech space.
Risks and Limitations
Volatility
IBB’s beta of 0.70 and a 5‑year drawdown of 39.8% signal higher volatility. Investors who cannot tolerate large swings may find IBB unsuitable.
Concentration Risk
With fewer holdings, IBB’s performance is more sensitive to the fortunes of a handful of companies. A regulatory setback or product failure can disproportionately impact the fund.
Dividend Yield
IBB’s dividend yield of 0.2% is low, and its dividend per share of $0.34 is modest compared to VHT’s $4.61 (Source: The Motley Fool coverage article, 2026-10-05). Income‑focused investors may prefer VHT.
Sector Impact
The healthcare sector has been a resilient performer, but the biotech sub‑sector has experienced sharper swings. VHT’s diversified approach buffers against sector‑specific shocks, while IBB’s focus on biotech can capture breakthroughs but also faces regulatory and clinical trial risks.
Business Implications for Investors
Cost Efficiency
VHT’s lower expense ratio reduces drag on returns, especially over long horizons. For investors who prioritize cost, VHT offers a more efficient vehicle.
Income vs Growth
If an investor’s priority is regular income, VHT’s higher dividend yield and stable payout make it attractive. Conversely, those seeking growth and willing to accept higher risk may lean toward IBB.
Portfolio Allocation
Adding VHT can provide broad sector coverage with minimal concentration, while IBB can serve as a high‑growth, high‑risk component. The choice depends on the investor’s overall asset allocation strategy.
Who May Be Affected
- Income‑seeking retirees: VHT’s higher yield aligns with income needs.
- Growth‑oriented young professionals: IBB’s biotech focus offers potential for higher capital appreciation.
- Risk‑averse investors: VHT’s lower beta and drawdown make it a safer option.
- Tax‑conscious investors: The lower expense ratio of VHT can reduce taxable gains.
What to Watch Next
- Regulatory developments: Biotech approvals or setbacks can swing IBB sharply.
- Pharmaceutical pipeline updates: New drug approvals for VHT’s top holdings can boost performance.
- Interest rate changes: Rising rates may affect dividend‑paying stocks in VHT.
- Market volatility: A broader market downturn could amplify IBB’s drawdown.
Conclusion
VHT vs IBB boils down to a trade‑off between breadth and depth. Vanguard’s Broad Health Care ETF offers lower costs, higher dividends, and a diversified portfolio that mitigates risk. iShares Biotechnology ETF delivers higher short‑term returns and growth potential but carries greater volatility and concentration risk. Investors should align their choice with their risk tolerance, income needs, and growth expectations.
FAQ
Q: Which ETF has a lower expense ratio?
A: Vanguard Health Care ETF (VHT) charges 0.09%, while iShares Biotechnology ETF (IBB) charges 0.44%.
Q: How do the dividend yields compare?
A: VHT offers a 1.4% dividend yield, whereas IBB provides 0.2%.
Q: Which fund performed better over the last year?
A: IBB delivered a 49.8% return, compared with VHT’s 22.5%.
Q: What is the risk profile of each ETF?
A: VHT has a beta of 0.58 and a 5‑year maximum drawdown of 17.7%, indicating lower volatility. IBB’s beta is 0.70 with a 5‑year drawdown of 39.8%, reflecting higher risk.
Q: Which ETF is more suitable for income investors?
A: VHT’s higher dividend yield and stable payouts make it more suitable for income‑focused investors.
Q: Which ETF offers greater growth potential?
A: IBB’s concentration in biotech and higher short‑term returns suggest greater growth potential, but it comes with higher volatility.
Q: How many holdings does each ETF have?
A: VHT holds 411 individual stocks; IBB holds 243.
Q: When were the ETFs launched?
A: VHT launched in 2004; IBB launched in 2001.
Q: What are the largest holdings in each ETF?
A: VHT’s top holdings are Eli Lilly & Co (12.82%), Johnson & Johnson (8.74%), and AbbVie Inc (6.27%). IBB’s top holdings are Gilead Sciences (8.16%), Vertex Pharmaceuticals (7.65%), and Amgen Inc (7.53%).
Q: Which ETF has a larger assets under management (AUM)?
A: VHT has $22.0 billion in AUM; IBB has $10.7 billion.
Q: What is the historical growth of a $1,000 investment?
A: Over five years, a $1,000 investment in VHT grew to $828, while in IBB it grew to $2,224.
Q: Where can I find more detailed data?
A: The Motley Fool coverage article dated 2026-10-05 provides comprehensive data and analysis.